Evidence map›Paper›PMID 38784674›Full record

ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2024

ANMCO/SIMEU consensus document on the use of reversal agents for antithrombotic therapies in patients with ongoing bleeding or at high risk of haemorrhagic events.

Leonardo De Luca, Francesco Rocco Pugliese, Beniamino Susi, Alessandro Navazio, Marco Corda, Andrea Fabbri, Pietro Scicchitano, Antonio Voza, Simone Vanni, Claudio Bilato and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal supplements : journal of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Leonardo De LucaDivision of Cardiology, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, 27100 Pavia, Italy.
Francesco Rocco PuglieseU.O.C. Medicina e Chirurgia d'Accettazione e d'Urgenza, Ospedale Sandro Pertini, Rome, Italy.
Beniamino SusiDipartimento di Emergenza, Policlinico Tor Vergata, Rome, Italy.
Alessandro NavazioS.O.C. Cardiologia Ospedaliera, Presidio Ospedaliero Arcispedale Santa Maria Nuova, Azienda USL di Reggio Emilia-IRCCS, Reggio Emilia, Italy.ORCID https://orcid.org/0000-0001-8417-7783
Marco CordaS.C. Cardiologia, Azienda Ospedaliera G. Brotzu, Cagliari, Italy.
Andrea FabbriDipartimento di Emergenza, AUSL Romagna, Presidio Ospedaliero Morgagni-Pierantoni, Forlì, Italy.
Pietro ScicchitanoU.O. Cardiologia-UTIC, Ospedale 'F. Perinei', Altamura, Italy.ORCID https://orcid.org/0000-0003-0471-0053
Antonio VozaDipartimento di Scienze Biomediche, IRCCS Humanitas Research Hospital, Milan, Italy.
Simone VanniDipartimento Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Claudio BilatoU.O.C. Cardiologia, Ospedali dell'Ovest Vicentino, Azienda ULSS 8 Berica, Vicenza, Italy.ORCID https://orcid.org/0000-0003-3474-0579
Giovanna GeraciU.O.C. Cardiologia, Ospedale Sant'Antonio Abate, Trapani, Italy.ORCID https://orcid.org/0000-0003-0092-8717
Domenico GabrielliDipartimento Cardio-Toraco-Vascolare, U.O.C. Cardiologia, Azienda Ospedaliera San Camillo Forlanini, Roma, Italy.
Massimo GrimaldiU.O.C. Cardiologia-UTIC, Ospedale Miulli, Acquaviva delle Fonti, Italy.ORCID https://orcid.org/0000-0002-9347-8884
Furio ColivicchiU.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri-ASL Roma 1, Rome, Italy.
Fabio De IacoS.C. Medicina di Emergenza-Urgenza, Ospedale Maria Vittoria, ASL Città di Torino, Turin, Italy.
Fabrizio OlivaUnità di Cure Intensive Cardiologiche, Cardiologia 1-Emodinamica, Dipartimento Cardiotoracovascolare 'A. De Gasperis', ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent decades, an incredible evolution in antithrombotic therapies used for treating patients with atherosclerosis, atrial fibrillation, and venous thromboembolism has been observed, leading to the availability of increasingly safe drugs. Nonetheless, bleeding complications remain a significant concern, with considerable health, social, and economic implications. To improve the acute management of patients experiencing or at risk for major bleeding events, specific reversal agents for antithrombotic drugs have been recently developed. While these agents demonstrate effectiveness in small-scale pharmacodynamic studies and clinical trials, it is imperative to balance the benefits of reversing antiplatelet or anticoagulant therapy against the risk of prothrombotic effects. These risks include the potential loss of antithrombotic protection and the prothrombotic tendencies associated with bleeding, major surgery, or trauma. This joint document of the Italian Association of Hospital Cardiologists (

Indexed as

Andexanet alfaAnticoagulantsAntiplateletsAntithrombotic agentsBentracimabIdarucizumabMajor bleedingReversal agents

Identifiers

PMID38784674
PMCPMC11110459

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.